Aeglea BioTherapeutics, Inc. Profile Avatar - Palmy Investing

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recomb…

Biotechnology
US, Austin [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Aeglea BioTherapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Aeglea BioTherapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Aeglea BioTherapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of AGLE's Analysis
CIK: 1636282 CUSIP: 00773J103 ISIN: US00773J2024 LEI: - UEI: -
Secondary Listings
AGLE has no secondary listings inside our databases.